← Search & browse all drugs
NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Fatty acid derivatives
progabide
N03AG05
Forms & Strengths
- Oral tablets: 200 mg, 300 mg, 600 mg
- Oral solution 50 mg/mL
Adult Dosing
- Start 300 mg/day in 2–3 divided doses
- Increase by 300 mg every 3‑5 days to therapeutic range 1200‑2400 mg/day
- Maximum dose 3600 mg/day
Pediatric Dosing
- 10‑20 mg/kg/day divided TID (max 30 mg/kg/day)
- Use only in refractory epilepsy; limited safety data
Indications
- Adjunctive treatment of refractory focal (partial) seizures
- Adjunctive treatment of generalized tonic‑clonic seizures not controlled by other AEDs
Mechanism of Action
- Prodrug rapidly converted to GABA in CNS
- Agonist at GABA‑B receptors, enhancing inhibitory neurotransmission
- Modulates voltage‑gated calcium channels, reducing neuronal excitability
Contraindications
- Known hypersensitivity to progabide or its excipients
- Severe hepatic insufficiency
- Pregnancy (risk to fetus; avoid unless essential)
Adverse Reactions
- Somnolence, dizziness, ataxia
- Nausea, vomiting, abdominal discomfort
- Weight gain, peripheral edema
- Elevated liver enzymes, occasional hepatitis
- Psychiatric effects (depression, anxiety)
- Rare worsening of seizure frequency
Drug Interactions
- Additive CNS depression with barbiturates, benzodiazepines, alcohol, antihistamines
- Enzyme inducers (phenytoin, carbamazepine, phenobarbital) decrease progabide levels
- Antacids reduce oral absorption of progabide
- Progabide may increase plasma concentrations of phenytoin and carbamazepine
Curated Content: Needs Vetting Before Put to Clinical Use